Angela Osborne
CEO, eXmoor Pharma
Osborne has over 30 years’ experience in biopharmaceutical and cell and gene therapy businesses, processes and facilities. Originally a biochemical engineer from University College London, Osborne is today the CEO and founder of eXmoor pharma (founded in 2004). She works closely with clients to guide and support them through new product expansion projects, from strategic business review to technical requirements and final solution delivery.
Prior to founding eXmoor, Osborne was Senior Vice President of Pharmaceuticals at Aker Kvaerner, an engineering multinational, where she was responsible for the pharmaceutical business in Europe, growing the turnover to equal the previously dominant chemicals business.
Osborne is a keen supporter of the UK’s BioIndustry Association, co-founder of the AMC (ATMP Manufacturing Community) and active contributor to the UCL Masters course in cell and gene manufacturing.
We asked…
What advice do you have for those new to the cell and gene field?
Early career professionals are very keen to progress quickly. However, it takes a truly multidisciplinary team to take a cell and gene therapy product to market, and being any part of that team will be hugely beneficial and a great learning experience. Focus on building that experience before starting to worry about job titles and positions.
If you weren’t in the pharma industry, what would you be doing instead?
I always saw myself doing something with horses until my physics teacher told me that would be a waste! I studied biochemical engineering because I liked math and biology, and wanted to end up in industry. During a summer placement doing bacterial fermentation at GD Searle in the US, I asked my supervisor what job I could do that would combine intellectual stimulation with being outside and he said, “when you find it, let me know.”
